ReviewFrontiers in immunology2025
Sequential anlotinib and camrelizumab combination therapy achieves exceptional survival in multi-driver mutated, TMB-low/PD-L1-low/MSS pulmonary sarcomatoid carcinoma: case report and literature review.
Jun Zhu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.